Zealand Pharma and Protagonist Therapeutics Team Up for Peptide Drug Discovery and Development

COPENHAGEN, Denmark & MENLO PARK, Calif.--(BUSINESS WIRE)--Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL), a Danish biotechnology company dedicated to the discovery and development of novel peptide drugs, has signed a collaboration agreement with Protagonist Therapeutics, Inc., a privately-owned US incorporated biotechnology company. Under the agreement, Zealand Pharma and Protagonist will join forces to identify, optimize and develop novel disulfide-rich peptides (DRPs) with the therapeutic potential to offer better treatment for patients in defined, non-disclosed disease areas.

Back to news